SUBSCRIBE
SUBSCRIBE

Longboard Pharmaceuticals

NEWS
Pictured: Bar and line graphs showing increasing t
Drug Development
Longboard Stock Skyrockets on Positive Epilepsy Data, Plans $150M Public Offering
Patients treated with Longboard Pharmaceuticals’ bexicaserin saw a 32.5% drop in the frequency of countable motor seizures relative to placebo in a Phase 1b/IIa study. The company’s shares soared 316% Tuesday on the news.
January 3, 2024
 · 
2 min read
 · 
Tristan Manalac
IN THE PRESS
Biotech Beach
Longboard Pharmaceuticals to Participate in Five Upcoming Epilepsy-Focused Conferences this Summer
June 1, 2022
 · 
7 min read
Biotech Beach
Longboard Pharmaceuticals to Participate in Upcoming Investor Events - May 12, 2022
May 12, 2022
 · 
2 min read
Business
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2022 Financial Results
May 5, 2022
 · 
9 min read
Drug Development
Longboard Pharmaceuticals to Present Phase 1 Data for LP352 at the American Academy of Neurology Annual Meeting
April 1, 2022
 · 
4 min read
Biotech Beach
Longboard Pharmaceuticals to Participate in Cantor Fitzgerald’s Virtual Rare Orphan Disease Summit
March 23, 2022
 · 
2 min read
Biotech Beach
Longboard Pharmaceuticals to Participate in Maxim Group 2022 Virtual Growth Conference
March 22, 2022
 · 
3 min read
Business
Longboard Pharmaceuticals Announces the Appointment of Highly Accomplished Healthcare Executive Randall Kaye, M.D., as Chief Medical Officer
March 21, 2022
 · 
4 min read
Business
Longboard Pharmaceuticals Provides Corporate Update and Reports Full Year 2021 Financial Results
March 3, 2022
 · 
11 min read
Biotech Beach
Longboard Pharmaceuticals to Present at the H.C. Wainwright BioConnect Virtual Conference
January 5, 2022
 · 
2 min read
Load More
JOBS